Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Scribe to Participate in the Leerink Partners Global Biopharma Conference
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
Scribe to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced an expanded collaboration with Sanofi (NASDAQ: SNY). Under the agreement, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of natural killer (NK) cell therapies for the treatment of cancer.
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following upcoming investor conferences in May and June:
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, will present data on its X-Editing (XE) technologies today at the 26th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held in Los Angeles, Calif. and virtually. The data validate the company’s CRISPR by Design™ approach as well as its XE technology as a potent and flexible platform for gene editing.
Eli Lilly’s Prevail Therapeutics is jotting down up to $1.5 billion for Scribe Therapeutics in hopes of writing some new CRISPR-based genetic medicines for neurological and neuromuscular diseases into history.
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design™ approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, Calif. and virtually from May 16-20, 2023.